Origin Biosciences

Origin Biosciences

Biotechnology, 421 Kipling St, Palo Alto, California, 94301, United States, 11-50 Employees

origintx.com

  • LinkedIn

phone no Phone Number: 65********

Who is ORIGIN BIOSCIENCES

Origin Biosciences, a subsidiary of BridgeBio Pharma, is a biotechnology company focused treatment for Molybdenum Cofactor Deficiency (MoCD). Origin is led by a team of veteran biotechnol...

Read More

map
  • 421 Kipling St, Palo Alto, California, 94301, United States Headquarters: 421 Kipling St, Palo Alto, California, 94301, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from ORIGIN BIOSCIENCES

Similar Companies to Origin Biosciences

Beam Therapeutics

  • 501-1000 501-1000
  • 50 Million to 100 Million $ 50 Million to 100 Million

BridgeBio

  • 201-500 201-500
  • 50 Million to 100 Million $ 50 Million to 100 Million

Eidos Therapeutics

  • 11-50 11-50
  • 10 Million to 25 Million $ 10 Million to 25 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Origin Biosciences

Answer: Origin Biosciences's headquarters are located at 421 Kipling St, Palo Alto, California, 94301, United States

Answer: Origin Biosciences's phone number is 65********

Answer: Origin Biosciences's official website is https://origintx.com

Answer: Origin Biosciences's revenue is $5 Million to $10 Million

Answer: Origin Biosciences's SIC: 8731

Answer: Origin Biosciences has 11-50 employees

Answer: Origin Biosciences is in Biotechnology

Answer: Origin Biosciences top competitors include: Beam Therapeutics , BridgeBio , Eidos Therapeutics

Answer: Origin Biosciences contact info: Phone number: 65******** Website: https://origintx.com

Answer: Origin Biosciences, a subsidiary of BridgeBio Pharma, is a biotechnology company focused treatment for Molybdenum Cofactor Deficiency (MoCD). Origin is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment for MoCD to market as quickly as possible.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access